Tag: oHCM

LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China

Coronary/Structural Heart by 0 comments

SHANGHAI, China and PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that CAMZYOS® (mavacamten) has received marketing approval for the […]

Continue Reading →

LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

Coronary/Structural Heart by 0 comments

EXPLORER-CN trial designed to support regulatory filing in Mainland China SHANGHAI, China and PRINCETON, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian […]

Continue Reading →